tiprankstipranks
Advertisement
Advertisement

AGIO Stock Latest News

Agios Pharma Kept at Hold as Analyst Weighs Cevidoplenib Opportunity Against Execution Risks; $32 Price Target Reaffirmed
RatingsAgios Pharma Kept at Hold as Analyst Weighs Cevidoplenib Opportunity Against Execution Risks; $32 Price Target Reaffirmed
4d ago
AGIO
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib
PremiumThe Fly
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib
5d ago
AGIO
Agios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path
PremiumCompany Announcements
Agios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path
8d ago
AGIO
Agios Advances Pediatric Mitapivat Trial in Transfusion-Dependent Thalassemia: What Investors Should Watch
PremiumCompany Announcements
Agios Advances Pediatric Mitapivat Trial in Transfusion-Dependent Thalassemia: What Investors Should Watch
8d ago
AGIO
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
8d ago
AGIO
Agios will not advance tebapivat in lower-risk myelodysplastic syndromes
PremiumThe FlyAgios will not advance tebapivat in lower-risk myelodysplastic syndromes
8d ago
AGIO
Agios announces EC grants marketing authorization for PYRUKYND
Premium
The Fly
Agios announces EC grants marketing authorization for PYRUKYND
15d ago
AGIO
Tessa Romero Reiterates Hold on Agios Pharma as Mitapivat Momentum Balances Competitive and Regulatory Uncertainties
Premium
Ratings
Tessa Romero Reiterates Hold on Agios Pharma as Mitapivat Momentum Balances Competitive and Regulatory Uncertainties
24d ago
AGIO
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat
PremiumThe Fly
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat
25d ago
AGIO
Agios Pharmaceuticals to present mitapivat data at EHA Congress
PremiumThe Fly
Agios Pharmaceuticals to present mitapivat data at EHA Congress
25d ago
AGIO
Agios Pharmaceuticals Earnings Call Signals Strong Momentum
PremiumCompany Announcements
Agios Pharmaceuticals Earnings Call Signals Strong Momentum
1M ago
AGIO
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist
1M ago
AGIO
Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
PremiumThe FlyAgios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
1M ago
AGIO
Is AGIO a Buy, Before Earnings?
Premium
Pre-Earnings
Is AGIO a Buy, Before Earnings?
1M ago
AGIO
Agios Pharmaceuticals price target lowered to $41 from $44 at BofA
Premium
The Fly
Agios Pharmaceuticals price target lowered to $41 from $44 at BofA
2M ago
NVO
AGIO
Maintaining Buy on Agios: Mitapivat’s Risk-Adjusted Upside Despite Etavopivat Competition and Regulatory Uncertainty
PremiumRatings
Maintaining Buy on Agios: Mitapivat’s Risk-Adjusted Upside Despite Etavopivat Competition and Regulatory Uncertainty
2M ago
AGIO
Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition
PremiumRatings
Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition
2M ago
AGIO
H.C. Wainwright cuts Agios target on smaller market post Novo data
PremiumThe Fly
H.C. Wainwright cuts Agios target on smaller market post Novo data
2M ago
NVO
AGIO
Agios Pharmaceuticals falls -23.4%
PremiumThe Fly
Agios Pharmaceuticals falls -23.4%
2M ago
AGIO
Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
PremiumThe FlyMidday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
2M ago
BX
DX
Agios Pharmaceuticals falls -23.7%
Premium
The Fly
Agios Pharmaceuticals falls -23.7%
2M ago
AGIO
Agios sinks after Novo Nordisk reports sickle cell data
Premium
The Fly
Agios sinks after Novo Nordisk reports sickle cell data
2M ago
NVO
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >